Core Viewpoint - Yangguang Nuohuo's STC008 injection is the first domestic drug under research for the treatment of cancer cachexia, with ongoing Phase I clinical trials showing promising interim data and no major safety issues reported [2] Group 1: Clinical Trial Progress - The Phase I clinical trial of STC008 is progressing smoothly, with interim data meeting predefined clinical objectives [2] - The timeline for advancing to Phase III clinical trials will be determined based on the complete data from Phase I, optimization of the trial protocol, and regulatory communications [2] - The company is committed to accelerating clinical work and will disclose trial progress to the market in accordance with legal and regulatory requirements to ensure investor awareness [2]

来源：市场资讯 针对上述提问，阳光诺和回应称："尊敬的投资者，您好！STC007注射液针对术后疼痛的临床试验正在 按既定方案稳步推进，目前各项临床工作有序开展，相关进展符合预期。关于上市申请时间，需根据临 床试验数据结果、统计分析及注册申报准备情况综合确定，公司将根据法律法规要求及时履行信息披露 义务。 市场竞争格局方面，目前国内术后疼痛治疗领域以传统镇痛药物为主，STC007以kappa阿片受体 （KOR）为靶点，强亲水性不易透过血脑屏障，可显著降低呼吸抑制、成瘾性等中枢系统副作用，且 镇痛持续时间更长，非精麻类处方便于临床使用，具有独特的作用机制与安全性优势，可满足临床未被 满足的需求。目前同靶点仅一家产品上市且已被纳入医保目录，后续公司将持续关注行业竞争动态，聚 焦产品临床价值与商业化落地，相关竞争信息以公开行业报告及公司公告为准。感谢您对公司的关 注。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向阳光诺和提问："STC007注射液针对术后疼痛的III期临床试验进展是否顺利？预 计何时提交上市申请？该品种的市场竞争格局如何？" ...

Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

Core Viewpoint - The company, Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd., has received a first-instance judgment in a lawsuit against Hunan Hengsheng Pharmaceutical Co., Ltd. for unpaid research fees totaling 620,000 yuan, along with overdue payment penalties [1][3] Group 1: Lawsuit Overview - The lawsuit pertains to Hunan Hengsheng's overdue payments for research fees related to 24 products, including "Ambroxol Hydrochloride Injection" and "Clindamycin Phosphate Injection" [2] - The court has ordered Hunan Hengsheng to pay the principal amount of 620,000 yuan and additional penalties calculated at a 5% annual interest rate from specified dates [3] Group 2: Financial Impact - The company has proactively accounted for the receivables from Hunan Hengsheng by fully provisioning for bad debts, indicating that the lawsuit will not negatively impact the company's current or future profits [1][3] - The final execution of the judgment remains uncertain as the case is still within the appeal period, and the actual impact will depend on the enforcement of the judgment [3]

证券代码：688621 证券简称：阳光诺和 公告编号：2026-003 北京阳光诺和药物研究股份有限公司 关于公司诉讼结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一审判决支付金额：湖南恒生制药股份有限公司（以下简称"恒生制药"） 向北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"或"公司"）支付拖 欠研发费用合计 62 万元及相应逾期支付违约金。 是否会对上市公司损益产生负面影响：公司根据审慎性原则按照会计准 则已对恒生制药应收账款和合同资产全额计提了坏账准备，因此该诉讼事项对公 司当期及期后利润不会构成负面影响。截至本公告日，本案尚处于上诉期内，最 终执行情况尚存在不确定性，对公司造成的具体影响需以生效判决的实际执行情 况为准。 一、本次重大诉讼的基本情况 2025 年 8 月 2 日，阳光诺和在上海证券交易所网站（www.sse.com.cn）披露 了《北京阳光诺和药物研究股份有限公司关于公司诉讼事项进展暨提起新诉讼的 公告》（公告编号：2025-061），公司就恒生制药拖欠公司" ...

证券之星消息，1月7日医疗服务板块较上一交易日上涨1.7%，益诺思领涨。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688710 | 益诺思 | 55.31 | 20.00% | 5.97万 | | 3.17亿 | | 688222 | 成都先导 | 30.44 | 13.67% | 44.49万 | | 13.43亿 | | 301293 | 三博脑科 | 93.82 | 10.45% | 74.53万 | | 68.62亿 | | 002173 | 创新医疗 | 28.63 | 9.99% | 10.16万 | | 2.91亿 | | 688621 | 阳光诺和 | 72.10 | 7.77% | 6.88万 | | 4.95 乙 | | 603127 | 昭衍新药 | 41.30 | 7.41% | 36.68万 | | 14.97亿 | | ...

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks, with notable gains including a 20% limit up for Beibetter-U and over 17% increase for Yinos [1] - Other significant performers included Chengdu XianDao with over 13% rise, and Panlong Pharmaceutical with a 10% limit up [1] - Additional stocks such as Sunshine Nuohuo and Zhaoyan New Drug also experienced increases of over 9% and 7% respectively [1] Group 2 - The table lists various stocks with their respective price changes, total market capitalization, and year-to-date performance, highlighting Beibetter-U's market cap at 18.6 billion and a year-to-date increase of 42.46% [2] - Yinos has a market cap of 7.611 billion with a year-to-date increase of 22.29%, while Chengdu XianDao's market cap is 12.2 billion with a 29.59% increase [2] - Other notable stocks include Panlong Pharmaceutical with a market cap of 3.706 billion and a 13.07% year-to-date increase, and Sunshine Nuohuo with a market cap of 8.188 billion and a 17.63% increase [2]

（文章来源：每日经济新闻） 每经AI快讯，1月7日，CRO指数震荡走高，成分股呈现普涨态势。成都先导涨逾10%，益诺思涨 7.70%，昭衍新药涨4.94%，美迪西涨2.82%，阳光诺和涨2.72%。 ...

Group 1 - The company announced a share repurchase plan to buy back its issued A-shares, with a total funding amount between RMB 50 million and RMB 100 million [1] - As of March 6, 2025, the company has repurchased a total of 2.721783 million shares, accounting for 2.43% of the total share capital, with a total payment of approximately RMB 99.97 million [2] - The company extended the loan agreement with China Postal Savings Bank from 12 months to 24 months, while the loan purpose remains unchanged [3]